Press release
Glioblastoma Multiforme (GBM) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Acerta, Ascletis, AstraZeneca, Bayer, BioMimetix, BioNTech, Celgene, Chimerix, Cytogel, Denovo Biopharma, DNAtrix
The expected launch of potential therapies may increase the Glioblastoma Multiforme market size in the coming years, assisted by an increase in the incident population of Glioblastoma Multiforme. The market is expected to witness a significant positive shift owing to the positive outcomes of several products during the developmental stage by key players such as Bayer, VBL Therapeutics, AstraZeneca, DNAtrix, Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology, Inovio Pharmaceuticals, Northwest Biotherapeutics, and others.
"Glioblastoma Multiforme (GBM) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Glioblastoma Multiforme Therapeutics Market.
The report provides a detailed description of the Glioblastoma Multiforme drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Glioblastoma Multiforme Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Glioblastoma Multiforme (GBM) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Glioblastoma Multiforme therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Multiforme treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Glioblastoma Multiforme drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Glioblastoma Multiforme treatment market.
Learn More about the Clinical and Commercial Development Activities in the Glioblastoma Multiforme Therapeutics Domain:
https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Glioblastoma Multiforme (GBM) Therapeutics Analysis
There are approx. 195+ key companies developing therapies for Glioblastoma Multiforme (GBM). Currently, Oncotelic Therapeutics is leading the therapeutics market with its Glioblastoma Multiforme drug candidates in the most advanced stage of clinical development.
Glioblastoma Multiforme (GBM) Companies in the Therapeutics Market Include:
3-V Biosciences, ACADIA Pharmaceuticals, Acerta Pharma, Aivita Biomedical, Array Biopharma, Ascletis, AstraZeneca, Autotelic Therapeutics, Bayer, BioMimetix, BioNTech, Bristol Myers Squibb, Celgene Corporation, Chimerix, CNS Pharmaceutical, Cytogel, Denovo Biopharma, DNAtrix, Doule bond Pharmaceuticals, Eisai and Merck Sharp & Dohme, Enterome, Epitopoietic Research Corporation (ERC), Forma Therapeutics, Genenta Science, Immatics N.V, Immunomic Therapeutics, Imvax, Inovio Pharmaceuticals, Istari Oncology, Karyo Pharma, Karyopharm Therapeutics, Kazia Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Mayo Clinic, Medicenna Therapeutics, MedImmune, Merck, MimiVax, Neugate Theranostics, Northwest Therapeutics, Novartis, Noxxon Pharma, Oblato, Oncotelic Therapeutics, Orphelia Pharma, Pfizer, Philogen, Roche, SonALAsense, TME Pharma, VBI Vaccines, Xgene Pharmaceutical, Yumanity Therapeutics, and many others
Emerging and Marketed Glioblastoma Multiforme (GBM) Therapies Covered in the Report Include:
Afatinib: Boehringer Ingelheim, AV-GBM-1: Aivita Biomedical, Avastin: Genentech, AZD1390: AstraZeneca, Crenolanib: AROG Pharmaceuticals, CYNK 001: Celularity, DCVax-L: Northwest Pharmaceuticals, Durvalumab (MEDI4736): MedImmune, G207: Treovir, ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics, LAM561 (2-OHOA): Laminar Pharmaceuticals, MDNA55: Medicenna Therapeutics, Ofranergene obadenovec (VB-111): VBL Therapeutics, ONC201: Chimerix, Onfekafuspalfa: Philogen, Paxalisib (GDC-0084): Kazia Therapeutics, PVSRIPO: Istari Oncology, Regorafenib: Bayer Healthcare, Research program: protein arginine N-methyltransferase 5 inhibitors: Jubilant Therapeutics, Selinexor (KPT-330): Karyopharm Therapeutics, Selinexor: Karyopharm Therapeutics, Tasadenoturev (DNX-2401): DNAtrix, Temodar/Temodal: Merck, Trabedersen: Oncotelic Therapeutics, Trans Sodium Crocetinate: Diffusion Pharmaceuticals, TVB2640:Ascletis Pharma, VAL-083 (Dianhydrogalactitol): Kintara Therapeutics, VBI-1901: VBI Vaccines, YTX7739: Yumanity Therapeutics, and many more.
Get an in-depth Assessment of the Emerging Therapies and Glioblastoma Multiforme Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Glioblastoma Multiforme Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Request for Sample PDF to Understand More About the Glioblastoma Multiforme Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Glioblastoma Multiforme Current Treatment Patterns
4. Glioblastoma Multiforme - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Glioblastoma Multiforme Late-Stage Products (Phase-III)
7. Glioblastoma Multiforme Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioblastoma Multiforme Discontinued Products
13. Glioblastoma Multiforme Product Profiles
14. Glioblastoma Multiforme Companies
15. Glioblastoma Multiforme Drugs
16. Dormant and Discontinued Products
17. Glioblastoma Multiforme Unmet Needs
18. Glioblastoma Multiforme Future Perspectives
19. Glioblastoma Multiforme Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Acute Ocular Pain Market
https://www.delveinsight.com/report-store/acute-ocular-pain-market
Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
Antibody-Mediated Graft Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-graft-rejection-market
Bacterial (Pyogenic) Meningitis Market
https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
Bevacizumab Biosimilars
https://www.delveinsight.com/report-store/bevacizumab-biosimilars-insight
Bronchial Neoplasm Market
https://www.delveinsight.com/report-store/bronchial-neoplasm-market
Calcinosis Cutis Market
https://www.delveinsight.com/report-store/calcinosis-cutis-market
Cardiovascular Calcification Market
https://www.delveinsight.com/report-store/cardiovascular-calcification-market
Dermal Regeneration Matrix Market
https://www.delveinsight.com/report-store/dermal-regeneration-matrix-market
Epstein Barr virus (EBV) Market
https://www.delveinsight.com/report-store/epstein-barr-virus-ebv-market
Glabellar Frown Lines Market
https://www.delveinsight.com/report-store/glabellar-frown-lines-market
Goitre Market
https://www.delveinsight.com/report-store/goitre-market
Hereditary Deafness Medical Device Market
https://www.delveinsight.com/report-store/hereditary-deafness-medical-devices-market
ICOS-Next Generation Immunotherapy Market
https://www.delveinsight.com/report-store/icos-next-generation-immunotherapy-competitive-landscape
Metrorrhagia Market
https://www.delveinsight.com/report-store/metrorrhagia-market
Nephrosclerosis Market
https://www.delveinsight.com/report-store/nephrosclerosis-market
Parkinson's Disease Related Dementia Market
https://www.delveinsight.com/report-store/parkinsons-disease-related-dementia-market
Peripherally Inserted Central Catheter (PICC) Devices Market
https://www.delveinsight.com/report-store/peripherally-inserted-central-catheter-picc-devices-market
Severe Toxicities in Lymphoma Market
https://www.delveinsight.com/report-store/severe-toxicities-in-lymphoma
Single Ventricle Heart Disease Market
https://www.delveinsight.com/report-store/single-ventricle-heart-disease-market
Small Fiber Neuropathy Market
https://www.delveinsight.com/report-store/small-fiber-neuropathy-market
Stuttering Market
https://www.delveinsight.com/report-store/stuttering-market
Venous Stenosis Market
https://www.delveinsight.com/report-store/venous-stenosis-market
Hyperopia Market
https://www.delveinsight.com/report-store/hyperopia-market
Microvascular Angina Market
https://www.delveinsight.com/report-store/microvascular-angina-market
Progressive Familial Intrahepatic Cholestasis Market
https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
CRISPR Therapies Pipeline Insight
https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight
Endometrial Hyperplasia Market
https://www.delveinsight.com/report-store/endometrial-hyperplasia-market
Adenoid Cystic Carcinoma Market
https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market
Chronic Pain Associated with Painful Diabetic Neuropathy Market
https://www.delveinsight.com/report-store/chronic-pain-associated-with-painful-diabetic-neuropathy-market
Contact Dermatitis Market
https://www.delveinsight.com/report-store/contact-dermatitis-market
Dermal Mycosis Market
https://www.delveinsight.com/report-store/dermal-mycosis-market
High-Grade Glioma Market
https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market
Lymphatic Malformations Market
https://www.delveinsight.com/report-store/lymphatic-malformations-market
Nocturnal Enuresis Market
https://www.delveinsight.com/report-store/nocturnal-enuresis-market
Ulcer Haemorrhage Market
https://www.delveinsight.com/report-store/ulcer-haemorrhage-market
Adult-onset Still Disease Market
https://www.delveinsight.com/report-store/adult-onset-still-disease-market
Alcohol Use Disorder (AUD) Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market
Cell And Gene Therapy For Multiple Myeloma Market
https://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market
Chronic Pancreatitis (CP) Market
https://www.delveinsight.com/report-store/chronic-pancreatitis-market
Cough in Idiopathic Pulmonary Fibrosis (IPF) Market
https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market
End-Stage Coronary Artery Disease Market
https://www.delveinsight.com/report-store/end-stage-coronary-artery-disease-market
Frontotemporal Dementia Market
https://www.delveinsight.com/report-store/frontotemporal-dementia-market
Cell and Gene Therapies in Rare Disorders Market
https://www.delveinsight.com/report-store/gene-and-cell-therapies-in-rare-disorder-market
Glycogen Storage Disease Market
https://www.delveinsight.com/report-store/glycogen-storage-disease-market
Maple Syrup Urine Disease Market
https://www.delveinsight.com/report-store/maple-syrup-urine-disease-market
MELAS Syndrome Market
https://www.delveinsight.com/report-store/melas-syndrome-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Multiforme (GBM) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Acerta, Ascletis, AstraZeneca, Bayer, BioMimetix, BioNTech, Celgene, Chimerix, Cytogel, Denovo Biopharma, DNAtrix here
News-ID: 3161833 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Glioblastoma
Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Adv …
Which drivers are expected to have the greatest impact on the over the glioblastoma multiforme market's growth?
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population,…
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
* DelveInsight's Glioblastoma pipeline report depicts…
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market…
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest…
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
DelveInsight's Recurrent Glioblastoma…
Revolutionizing Glioblastoma Treatment Strategies: A Deep Dive into the Glioblas …
The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements.
Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players…
